SPRY4-IT1 expression is significantly related to breast cancer resistance to cisplatin, and increased SPRY4-IT1 expression is significantly associated with the lymph node metastasis rate and recurrence; in addition, patients with high spRY4-IT1 expression have lower OS and DFS rates than those with low expression (Zheng et al., 2020). This evidence concerns the gene SPRY4 and metastatic malignant neoplasm in the lymph nodes.